AR040157A1 - A FORMULATION IN MICROGRANULES FOR ORAL ADMINISTRATION IN WATERPROOF SUSPENSION - Google Patents

A FORMULATION IN MICROGRANULES FOR ORAL ADMINISTRATION IN WATERPROOF SUSPENSION

Info

Publication number
AR040157A1
AR040157A1 ARP030102011A AR040157A1 AR 040157 A1 AR040157 A1 AR 040157A1 AR P030102011 A ARP030102011 A AR P030102011A AR 040157 A1 AR040157 A1 AR 040157A1
Authority
AR
Argentina
Prior art keywords
active ingredient
formulation
particles
coating
layer
Prior art date
Application number
Other languages
Spanish (es)
Original Assignee
Rodriguez Julio Cesar
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rodriguez Julio Cesar filed Critical Rodriguez Julio Cesar
Priority to ARP030102011 priority Critical patent/AR040157A1/en
Priority to PCT/US2004/017862 priority patent/WO2004108089A2/en
Publication of AR040157A1 publication Critical patent/AR040157A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Composición en partículas para resuspender en una solución acuosa para el tratamiento de enfermedades y método para su obtención, donde las partículas comprenden por lo menos un principio activo de entre 10 y 90 micrones de tamano de partícula y entre un 10% y 70% p/p respecto del peso total de la composición de una capa de recubrimiento lipídica. Además se refiere a una formulación en forma de partículas recubiertas que puede ser usada para obtener una suspensión acuosa para el tratamiento de enfermedades o para administración durante un método de diagnóstico. Más particularmente, la composición comprende una formulación en forma de micro gránulos para administración oral en una suspensión acuosa, siendo la formulación capaz de resistir su dilución o disolución mientras se encuentra en la solución acuosa pero siendo capaz de liberar rápidamente un ingrediente activo en un medio gastrointestinal con bajo pH, comprendiendo la formulación un sistema multi-capas para el enmascaramiento del sabor del ingrediente activo. Reivindicación 2: La composición en partículas de acuerdo con la reivindicación 1, caracterizada porque el producto farmacéutico es seleccionado del grupo comprendido por fosfatos, bifosfonatos, analgésicos, anti-inflamatorios no esteroides, y corticoides. Reivindicación 3: La composición en partículas de acuerdo con la reivindicación 1, caracterizada porque el recubrimiento lipídico es un lípido con un punto de fusión entre 38°C y 75°C. Reivindicación 10: Un método para preparar la composición en partículas de la reivindicación 1, caracterizada porque, comprende las siguientes etapas: i. Secar y moler un producto farmacéutico para obtener partículas de un tamano entre 10 y 90 micrones; ii. recubrir el principio activo en partículas con un material lípido de recubrimiento; iii. introducir el principio activo recubierto obtenido en la etapa ii) en un equipo de secado por rocío impulsado por una corriente de gas a una temperatura entre 0°C y 55°C; y iv. tamizar las partículas recubiertas para obtener partículas que tienen un tamano uniforme deseado. Reivindicación 19: Una formulación de gránulos para administrarse en una suspensión acuosa, capaz de enmascarar el sabor de un ingrediente activo y proveer una rápida liberación del ingrediente activo en el medio gastrointestinal, la formulación comprende gránulos, caracterizada porque cada gránulo comprende: i. Un núcleo central de azúcar que tiene un tamano entre alrededor de 200 y alrededor de 600 micrones; ii. una capa adhesiva polimérica que rodea y recubre al núcleo central; iii. una capa de ingrediente activo que comprende al menos un ingrediente activo en polvo que tiene un tamano de partícula menor de 100nm, y iv. una capa para enmascarar el sabor que comprende un recubrimiento que es soluble a un pH entre alrededor de 7.0 y alrededor de 2.5, en donde el recubrimiento es capaz de resistir la disolución en una suspensión acuosa para enmascarar el sabor del ingrediente activo y es capaz de proveer una rápida liberación del ingrediente activo en el medio gastrointestinal.Composition in particles to resuspend in an aqueous solution for the treatment of diseases and method for obtaining them, where the particles comprise at least one active ingredient of between 10 and 90 microns of particle size and between 10% and 70% w / p with respect to the total weight of the composition of a layer of lipid coating. It also refers to a formulation in the form of coated particles that can be used to obtain an aqueous suspension for the treatment of diseases or for administration during a diagnostic method. More particularly, the composition comprises a formulation in the form of micro granules for oral administration in an aqueous suspension, the formulation being able to resist dilution or dissolution while in the aqueous solution but being able to rapidly release an active ingredient in a medium. gastrointestinal with low pH, the formulation comprising a multi-layer system for masking the flavor of the active ingredient. Claim 2: The particulate composition according to claim 1, characterized in that the pharmaceutical product is selected from the group consisting of phosphates, bisphosphonates, analgesics, non-steroidal anti-inflammatories, and corticosteroids. Claim 3: The particulate composition according to claim 1, characterized in that the lipid coating is a lipid with a melting point between 38 ° C and 75 ° C. Claim 10: A method for preparing the particulate composition of claim 1, characterized in that it comprises the following steps: i. Dry and grind a pharmaceutical product to obtain particles of a size between 10 and 90 microns; ii. coating the active ingredient in particles with a lipid coating material; iii. introducing the coated active ingredient obtained in step ii) in a spray drying equipment driven by a gas stream at a temperature between 0 ° C and 55 ° C; and iv. screen the coated particles to obtain particles that have a desired uniform size. Claim 19: A formulation of granules to be administered in an aqueous suspension, capable of masking the taste of an active ingredient and providing rapid release of the active ingredient in the gastrointestinal medium, the formulation comprises granules, characterized in that each granule comprises: i. A central sugar core that has a size between about 200 and about 600 microns; ii. a polymeric adhesive layer that surrounds and covers the central core; iii. an active ingredient layer comprising at least one active ingredient powder having a particle size of less than 100 nm, and iv. a layer for masking the taste that comprises a coating that is soluble at a pH between about 7.0 and about 2.5, wherein the coating is able to resist dissolution in an aqueous suspension to mask the taste of the active ingredient and is capable of provide a rapid release of the active ingredient in the gastrointestinal environment.

ARP030102011 2003-06-06 2003-06-06 A FORMULATION IN MICROGRANULES FOR ORAL ADMINISTRATION IN WATERPROOF SUSPENSION AR040157A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
ARP030102011 AR040157A1 (en) 2003-06-06 2003-06-06 A FORMULATION IN MICROGRANULES FOR ORAL ADMINISTRATION IN WATERPROOF SUSPENSION
PCT/US2004/017862 WO2004108089A2 (en) 2003-06-06 2004-06-07 A micro granulate formulation for oral administration in aqueous suspension

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ARP030102011 AR040157A1 (en) 2003-06-06 2003-06-06 A FORMULATION IN MICROGRANULES FOR ORAL ADMINISTRATION IN WATERPROOF SUSPENSION

Publications (1)

Publication Number Publication Date
AR040157A1 true AR040157A1 (en) 2005-03-16

Family

ID=33494452

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030102011 AR040157A1 (en) 2003-06-06 2003-06-06 A FORMULATION IN MICROGRANULES FOR ORAL ADMINISTRATION IN WATERPROOF SUSPENSION

Country Status (2)

Country Link
AR (1) AR040157A1 (en)
WO (1) WO2004108089A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101340733B1 (en) * 2012-12-31 2013-12-12 (주) 에프엔지리서치 Novel microgranule preparations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214386B1 (en) * 1995-11-22 2001-04-10 Recordati, S.A. Prompt-release oral pharmaceutical compositions for extemporaneous suspensions
US20030086972A1 (en) * 2000-08-09 2003-05-08 Appel Leah E. Hydrogel-driven drug dosage form
US8071133B2 (en) * 2001-08-20 2011-12-06 Stiefel Laboratories, Inc. Oral dosage forms of water insoluble drugs and methods of making the same
US6986901B2 (en) * 2002-07-15 2006-01-17 Warner-Lambert Company Llc Gastrointestinal compositions

Also Published As

Publication number Publication date
WO2004108089A3 (en) 2005-03-24
WO2004108089A2 (en) 2004-12-16

Similar Documents

Publication Publication Date Title
El-Samaligy et al. Increasing bioavailability of silymarin using a buccal liposomal delivery system: preparation and experimental design investigation
Patil et al. Recent advancements in mucoadhesive floating drug delivery systems: A mini-review
DK175593B1 (en) Particulate preparation of cefuroxime maxetil, wherein the particles are coated with lipids, and a process for their preparation
KR930006431B1 (en) Microcapsulation of drugs
ES2706152T3 (en) Enteral composition of multiple particles coated with protein subcoat
DE60010464T2 (en) TASTE-COATED LIQUID MEDICINE PREPARATIONS
ES2688889T3 (en) Solvent-free mixing process for coating pharmaceutical ingredients
WO2015160842A1 (en) Methods and formulatiions of capsaicinoids and capsinoids
JP6025755B2 (en) Multiparticulate L-menthol formulations and related methods
PL196163B1 (en) Novel form of a drug for oral administration of active compounds being unstable in acid environments
SK18022001A3 (en) Administration form of acid-labile active compounds, an active compound unit, a method for producing same and a microsphere
JPH0259515A (en) Pharmaceutical composition of oral administration having analgestic activity anti-inflammatory activity and excellent favorite properties and showing no mucous
JP2011509947A (en) Drug delivery system and method and use thereof
Wagh et al. Taste masking methods and techniques in oral pharmaceuticals: current perspectives
Silva et al. Sustainable strategies for nano-in-micro particle engineering for pulmonary delivery
AU2008337269A1 (en) Formulations comprising exine shells
JPH02180813A (en) Granulated formulation
KR20120006085A (en) Masking the taste of powders
JP2021515034A (en) Transmucosal film composition and methods for making and using it
WO1997027842A1 (en) Water soluble pharmaceutical coating and method for producing coated pharmaceuticals
BR112021016421A2 (en) MINIMIZATION OF AGLOMERATION, AERATION AND COATING PRESERVATION OF PHARMACEUTICAL COMPOSITIONS INCLUDING IBUPROFENE
Choudhary et al. Stomach specific polymeric low density microballoons as a vector for extended delivery of rabeprazole and amoxicillin for treatment of peptic ulcer
ES2584403T3 (en) Process for the preparation of enteric alginate microcapsules by ionic gelation containing diclofenac or one of its salts and multiparticulate pharmaceutical composition containing them
Del Gaudio et al. Submicrometric hypromellose acetate succinate particles as carrier for soy isoflavones extract with improved skin penetration performance
WO2004087111A1 (en) Oral taste masked pharmaceutical compositions

Legal Events

Date Code Title Description
FB Suspension of granting procedure